Shire

10 marketed · 29 in Phase 3

Quick facts

Marketed products

C1 Esterase Inhibitor (Human) · Immunology; Rare Genetic Disorders
C1 esterase inhibitor (C1-INH) suppresses activation of the contact system and complement cascade by inhibiting plasma kallikrein and Factor XIIa, thereby reducing bradykinin generation and preventing angioedema attacks.
C1 inhibitor (human) [C1 INH] · Immunology / Rare disease
C1 inhibitor (human) is a plasma protein that regulates the initial step of the classical complement cascade by inhibiting C1s protease activity.
Dynepo · Other
Elaprase · Other
MMX Mesalamine · Gastroenterology / Immunology
MMX Mesalamine is a delayed-release formulation of mesalamine that delivers the anti-inflammatory drug to the colon to reduce inflammation in inflammatory bowel disease.
MMX mesalamine/ mesalazine · Gastroenterology / Immunology
MMX mesalamine is an anti-inflammatory agent that reduces inflammation in the colon by inhibiting prostaglandin and leukotriene production.
Replagal (agalsidase alfa) · Rare genetic disease / Lysosomal storage disorder
Agalsidase alfa is a recombinant human enzyme that replaces deficient α-galactosidase A, breaking down accumulated globotriaosylceramide in cells.
rhPTH (1-84) · Endocrinology
rhPTH (1-84) is a recombinant human parathyroid hormone that binds to PTH1 receptors on bone cells to stimulate bone formation and increase serum calcium and phosphate levels.
SPD489 · Other
TED · Neurology / Psychiatry
TED is a prodrug that is converted to active metabolites to treat attention-deficit/hyperactivity disorder (ADHD) by enhancing central nervous system stimulation.

Phase 3 pipeline

ALX1-11
ALX1-11 (drug) · Oncology
ALX1-11 is a monoclonal antibody that blocks the Wnt signaling pathway by targeting Wnt ligands, thereby inhibiting aberrant cell proliferation and differentiation.
C1 esterase inhibitor [human] liquid · Immunology; Rare Genetic Disorders
C1 esterase inhibitor replaces or augments the deficient or dysfunctional C1 inhibitor protein, which normally suppresses excessive activation of the contact system and complement cascade.
CINRYZE 1000 · Immunology / Rare Disease
CINRYZE is a plasma kallikrein inhibitor that reduces bradykinin production to prevent acute attacks in hereditary angioedema.
CINRYZE 1000 U · Immunology / Rare Genetic Disorders
CINRYZE is a C1 esterase inhibitor (C1-INH) that replaces or augments deficient or dysfunctional C1 inhibitor protein to prevent excessive bradykinin generation and control hereditary angioedema attacks.
CINRYZE 500 · Immunology / Rare Genetic Disorders
CINRYZE is a C1 esterase inhibitor (C1-INH) that suppresses activation of the contact system to prevent bradykinin-mediated angioedema attacks.
CINRYZE 500 U · Immunology / Rare Genetic Disorders
CINRYZE is a C1 esterase inhibitor (C1-INH) that replaces deficient or dysfunctional C1 inhibitor protein to prevent excessive bradykinin generation and control hereditary angioedema attacks.
Delayed and extended release mesalazine · Gastroenterology
Mesalazine (5-aminosalicylic acid) reduces intestinal inflammation by inhibiting prostaglandin and leukotriene production and scavenging reactive oxygen species in the colon.
DX-2930 · Cardiovascular
DX-2930 is a Factor XIIa inhibitor that reduces contact pathway activation to prevent thrombosis without affecting primary hemostasis.
Fosrenol (Lanthanum Carbonate) · Nephrology
Lanthanum carbonate binds to phosphate in the gastrointestinal tract, forming insoluble complexes that are eliminated in feces, thereby reducing serum phosphate levels.
lumbar puncture
Lumbar puncture is a diagnostic procedure, not a drug, and does not have a pharmacological mechanism.
MHOS/SHP615 · Endocrinology
MHOS/SHP615 is a long-acting growth hormone secretagogue (ghrelin receptor agonist) that stimulates growth hormone release.
NPSP558 · Cardiovascular
NPSP558 is a selective vasopressin V1a receptor antagonist that blocks vasopressin signaling to reduce aquaporin-2 water channel expression and increase urine output.
PEG 4000 · Gastroenterology
PEG 4000 is an osmotic laxative that draws water into the intestinal lumen to soften stool and promote bowel movements.
Phosphate Buffer Saline (PBS),
PBS is a buffered saline solution that maintains physiological pH and osmolarity, serving as a vehicle or diluent rather than an active pharmaceutical agent.
PTH/Calcium · Endocrinology
This combination therapy works by supplementing parathyroid hormone (PTH) to regulate calcium homeostasis and bone metabolism.
SHP615 · Cardiovascular
SHP615 is a monoclonal antibody targeting the PCSK9 protein.
SPD476 · Psychiatry
SPD476 is a small molecule drug that targets the serotonin receptor.
SPD476 (1.2g) · Unknown
SPD476 is a small molecule drug that targets the molecular target.
SPD476 (2.4 g) · Psychiatry/Neurology
SPD476 is a monoamine oxidase inhibitor that increases levels of dopamine, norepinephrine, and serotonin in the central nervous system.
SPD476 (4.8 g) · Diabetes
SPD476 is a small molecule drug that targets the SGLT2 receptor.
SPD476 (mesalazine) · Gastroenterology
SPD476 (mesalazine) works by inhibiting the enzyme aminopeptidase N to reduce inflammation in the gut.
SPD503 (1 mg) · Respiratory / Immunology
SPD503 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
SPD503 (2 mg) · Neurology
SPD503 is a dopamine receptor agonist.
SPD503 (3 mg) · Respiratory / Immunology
SPD503 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
SPD503 (4 mg) · Respiratory / Immunology
SPD503 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.
SPD503-AM · Psychiatry/Neurology
SPD503-AM is a monoamine oxidase inhibitor that increases levels of dopamine, norepinephrine, and serotonin in the central nervous system.
SPD503 (Guanfacine HCl) · Neurology / Psychiatry
Guanfacine is an alpha-2A adrenergic receptor agonist that reduces norepinephrine activity in the prefrontal cortex to improve attention and impulse control.
SPD503-PM · Psychiatry
SPD503-PM is a small molecule drug that targets the serotonin receptor.

Phase 2 pipeline

Phase 1 pipeline

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Shire

What are Shire's marketed drugs?

Top marketed products include C1 Esterase Inhibitor (Human), C1 inhibitor (human) [C1 INH], Dynepo, Elaprase, MMX Mesalamine, MMX mesalamine/ mesalazine.

What is Shire's pipeline?

Shire has 29 drugs in Phase 3, 11 in Phase 2, 24 in Phase 1. Late-stage candidates include ALX1-11, ALX1-11 (drug), C1 esterase inhibitor [human] liquid, CINRYZE 1000.

C1 Esterase Inhibitor (Human) · Immunology; Rare Genetic Disorders
C1 inhibitor (human) [C1 INH] · Immunology / Rare disease
Dynepo · Other
Elaprase · Other
MMX Mesalamine · Gastroenterology / Immunology
Sector hub: All tracked pharma companies